89 related articles for article (PubMed ID: 38414930)
1. EGFR and HER2 expression in cervical cancer patients in Ibadan, Nigeria.
Orekoya AA; Abdus-Salam AA; Oyesegun AR; Ntekim AI; Folasire AM; Okolo CA; Olabumuyi AA; Dada AA; Adenipekun AA
Ecancermedicalscience; 2023; 17():1607. PubMed ID: 38414930
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
3. Epidermal Growth Factor Receptor Expression of Colorectal Carcinoma in Nigerian Patients.
Lawan AI; Ogunbiyi JO
West Afr J Med; 2020; 37(2):100-105. PubMed ID: 32150626
[TBL] [Abstract][Full Text] [Related]
4. EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy.
Shen L; Shui Y; Wang X; Sheng L; Yang Z; Xue D; Wei Q
BMC Cancer; 2008 Aug; 8():232. PubMed ID: 18700025
[TBL] [Abstract][Full Text] [Related]
5. Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer.
Nishio S; Ushijima K; Yamaguchi T; Sasajima Y; Tsuda H; Kasamatsu T; Kage M; Ono M; Kuwano M; Kamura T
Gynecol Oncol; 2014 Mar; 132(3):703-8. PubMed ID: 24486603
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study.
Aisner SC; Dahlberg S; Hameed MR; Ettinger DS; Schiller JH; Johnson DH; Aisner J; Loehrer PJ
J Thorac Oncol; 2010 Jun; 5(6):885-92. PubMed ID: 20421818
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Value of Cancer Stem Cell Markers in Cervical Cancer: A Systematic Review and Meta-Analysis.
Fahmi MN; Hertapanndika IN; Kusuma F
Asian Pac J Cancer Prev; 2021 Dec; 22(12):4057-4065. PubMed ID: 34967589
[TBL] [Abstract][Full Text] [Related]
8. Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer.
Fleischmann M; Chatzikonstantinou G; Fokas E; Wichmann J; Christiansen H; Strebhardt K; Rödel C; Tselis N; Rödel F
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830902
[TBL] [Abstract][Full Text] [Related]
9. Precision medicine for cervical cancer.
Manrriquez EN; Zakhour M; Salani R
Curr Opin Obstet Gynecol; 2022 Feb; 34(1):1-5. PubMed ID: 34596094
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.
Itkin B; Garcia A; Straminsky S; Adelchanow ED; Pereyra M; Haab GA; Bardach A
PLoS One; 2021; 16(9):e0257976. PubMed ID: 34591928
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Role of Matrix Metalloproteinases in Cervical Cancer: A Meta-Analysis.
Chen W; Huang S; Shi K; Yi L; Liu Y; Liu W
Cancer Control; 2021; 28():10732748211033743. PubMed ID: 34482737
[TBL] [Abstract][Full Text] [Related]
12. EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance.
Uribe ML; Marrocco I; Yarden Y
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34206026
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and meta-analysis of the prevalence of therapeutic targets in cervical cancer.
Patrono MG; Calvo MF; Franco JVA; Garrote V; Vietto V
Ecancermedicalscience; 2021; 15():1200. PubMed ID: 33889209
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
